Literature DB >> 11311235

Human anti-asparaginyl-tRNA synthetase autoantibodies (anti-KS) increase the affinity of the enzyme for its tRNA substrate.

M Beaulande1, M Kron, M Hirakata, M Härtlein.   

Abstract

Autoantibodies directed against specific human aminoacyl-tRNA synthetases have been associated with a clinical picture including myositis, arthritis, interstitial lung disease and other features that has been referred to as the "anti-synthetase syndrome". Anti-asparaginyl-tRNA synthetase autoantibodies (anti-KS), the most recently described anti-synthetase autoantibodies, are directed against human cytosolic asparaginyl-tRNA synthetase and neutralize specifically its activity. Here we show that these antibodies recognize two epitopes on the human enzyme, an N-terminal epitope reactive in immunoblot experiments and a heat-labile epitope in the catalytic domain. In contrast to the well studied anti-Jo-1 autoantibodies anti-KS when bound to the synthetase increase the affinity of the synthetase for its tRNA substrate and prevent aminoacylation without interfering with the amino acid activation step.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311235     DOI: 10.1016/s0014-5793(01)02340-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Dynamic Organization of Aminoacyl-tRNA Synthetase Complexes in the Cytoplasm of Human Cells.

Authors:  Monika Kaminska; Svitlana Havrylenko; Paulette Decottignies; Pierre Le Maréchal; Boris Negrutskii; Marc Mirande
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

Review 2.  Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome.

Authors:  Yongpeng Ge; Sizhao Li; Shanshan Li; Linrong He; Xin Lu; Guochun Wang
Journal:  Ther Adv Chronic Dis       Date:  2020-10-29       Impact factor: 5.091

3.  A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  bioRxiv       Date:  2021-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.